Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 62/501,984, filed May 5, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,611,787 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof In force · High confidence | Bold Therapeutics, Inc. | In force | High confidence | ||
| US 11,040,993 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof In force · High confidence | Bold Therapeutics, Inc. | In force | High confidence | ||
| US 11,739,111 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof In force · High confidence | Bold Therapeutics, Inc. | In force | High confidence | ||
| US 12,415,825 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof In force · High confidence | Bold Therapeutics, Inc. | In force | High confidence | ||
| Application 19/277,690 | Manufacture of TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] and Compositions Thereof Pending Not granted | Bold Therapeutics, Inc. | Pending | Not granted | not computed |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Bold Limited.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.